AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer

AnHeart Therapeutics together with Innovent Biologics, Inc. jointly announced that the Center for Drug Evaluation of China’s Nation Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to taletrectinib.